Opioid use disorder (OUD) is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s investigational product is developed with an aim to support patients with OUD as they focus on the reintegration of their lives and communities.
1HHS.gov, Oct 2019, Opioid epidemic by Numbers, Accessed 02/27/2020 https://www.hhs.gov/opioids/about-the-epidemic/index.html
FluidCrystal®* Injection Depot Technology, a next generation proprietary delivery system, includes a lipid-based liquid with a dissolved active ingredient. Upon injection and contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which encapsulates the active ingredient, allowing for a slow release of the medication over time.
*FluidCrystal® trademark is owned by Camurus and used by Braeburn under license.
We are collaborative. We are passionate. We are proud of our purpose.
At Braeburn, there are opportunities to contribute to our purpose every day. We value authenticity and strive to amplify all voices. Our culture empowers everyone to be successful and unleashes our full potential.